--- title: "BriaCell Therapeutics regains compliance" url: "https://aibio.space/news/briacell-therapeutics-regains-compliance-nasdaq-minimum-bid-price/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-02-13" section: "Listings" tickers: "TSX:BCT, NASDAQ:BCTX" source: "https://www.sec.gov/Archives/edgar/data/1610820/000149315225006419/form8-k.htm" summary: "Nasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.0" --- By the aibio.space news desk. Sources - [BriaCell Therapeutics Corp 8-K (2025-02-13)](https://www.sec.gov/Archives/edgar/data/1610820/000149315225006419/form8-k.htm) - [BriaCell Therapeutics Corp 10-K (2024-10-29): business](https://www.sec.gov/Archives/edgar/data/1610820/000149315224042743/form10-k.htm) [BCT](https://aibio.space/companies/briacell-therapeutics/) [BCTX](https://aibio.space/companies/briacell-therapeutics-bctx/) 2025-02-13 # BriaCell Therapeutics regains compliance with Nasdaq minimum bid price requirement Tickers [BCT](https://aibio.space/companies/briacell-therapeutics/)[BCTX](https://aibio.space/companies/briacell-therapeutics-bctx/) Nasdaq closed BriaCell's bid price matter on February 12, 2025, after an August 2024 letter cited 30 consecutive business days with closing bids below $1.00. ## Key facts - **Companies**: BriaCell Therapeutics Corp (TSX: BCT), BriaCell Therapeutics Corp. (NASDAQ: BCTX) - **News type**: Listings - **Primary source**: [BriaCell Therapeutics Corp 8-K (2025-02-13)](https://www.sec.gov/Archives/edgar/data/1610820/000149315225006419/form8-k.htm) *The facade of a neoclassical court building at dusk. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* BriaCell Therapeutics Corp. (Nasdaq: [BCTX](https://aibio.space/companies/briacell-therapeutics-bctx/)) said in a Form 8-K filed on February 13, 2025 that it has regained compliance with Nasdaq's minimum bid price requirement. It says the company received written notice on February 12, 2025, from the staff of The Nasdaq Stock Market, that the matter is now closed. The 8-K is signed by William V. Williams, the company's president and chief executive officer. The company's principal office is in Vancouver, British Columbia. ## The bid price letter The 8-K says the company received a letter from Nasdaq's Listing Qualifications Department on August 22, 2024. The letter said that, based on the closing bid price over the prior 30 consecutive business days, the company did not meet the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The 8-K describes that letter as previously disclosed, but it does not repeat the closing prices or the dates within the 30-day window. The February notice says the company has regained compliance and the matter is closed. The 8-K does not say what share price the company traded at during the period that satisfied the rule, what steps it took in between, or whether it asked for a hearing. The company's common shares trade on Nasdaq under the symbol BCTX, and its warrants under BCTXW. The 8-K checks the box identifying the company as an emerging growth company. ## The lead program The company's annual report, filed in October 2024, describes BriaCell as a clinical-stage biotechnology company developing immunotherapies. Its lead program is Bria-IMT, a targeted immunotherapy given with retifanlimab, an immune checkpoint inhibitor, in a pivotal Phase 3 study in metastatic breast cancer. The report says Bria-IMT has Fast Track designation from the FDA. It also says that positive completion of the pivotal study, followed by FDA review, could lead to full approval of the combination in metastatic breast cancer. The report cites a median overall survival of 13.4 months in its metastatic breast cancer patients, against 6.7 to 9.8 months for similar patients reported in the literature. The comparison comes from a Phase 2 study presented at the 2023 San Antonio Breast Cancer Symposium. The report also cites a median overall survival of 15.6 months in Phase 2 patients treated with the Phase 3 formulation since 2022. These figures compare different studies, so they cannot show that the difference came from the drug. The report says a completed Phase 1 combination study with retifanlimab confirmed tolerability and early-stage efficacy. It also describes Bria-OTS, a personalized off-the-shelf immunotherapy platform, and says that in September 2024 the company reported positive feedback from a Pre-IND meeting with the FDA for Bria-PROS+ in prostate cancer. ## The market figures The report cites National Cancer Institute estimates that about 310,720 women in the United States would be diagnosed with breast cancer in 2024, and that more than 42,250 were projected to die. It puts the five-year survival rate for patients who have metastatic disease at diagnosis at 30%. For patients who have received two or more prior lines of therapy, it cites a median survival of 5.9 to 9.8 months. The report also cites an IQVIA estimate that the global cancer drug market will reach nearly $375 billion by the end of 2027. These are third-party estimates used to frame the opportunity. They are not forecasts of BriaCell's sales. ## What the notice leaves out A bid price rule tests the share price alone. The 8-K says nothing about cash, losses, share count or whether the pivotal study is funded. The annual report predates the notice, so its financial information cannot describe the company's position in February 2025. The record leaves two questions open. The first is whether the stock stays above the minimum. The second is whether the pivotal Phase 3 study can be funded to completion. The 8-K speaks only to the first, and only as of its date. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story BCT BriaCell Therapeutics Corp TSX · Canada Open the starter desk BCTX BriaCell Therapeutics Corp. NASDAQ · Not recorded Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/briacell-therapeutics-regains-compliance-nasdaq-minimum-bid-price/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BriaCell Therapeutics regains compliance", 2025-02-13, https://aibio.space/news/briacell-therapeutics-regains-compliance-nasdaq-minimum-bid-price/